Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 9/20 | 0.52 |
| ▸ | ACLY | P53396 | 4/20 | 0.48 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6408135 | 0.88 | KCNMA1 (0.55) | KCNMA1HSPA5POLBCHRNA7STAT3 | |
| SCHEMBL6415342 | 0.83 | HSPA5 (0.47) | KCNMA1HSPA5POLBCHRNA7STAT3 | |
| SCHEMBL6410292 | 0.83 | HSPA5 (0.62) | ACLYHSPA5POLBKDM4EHIF1A | |
| SCHEMBL6417211 | 0.82 | CHRNA7 (0.63) | KCNMA1HSPA5CHRNA7P2RX1 | |
| SCHEMBL6414640 | 0.82 | ACLY (0.49) | KCNMA1ACLYHSPA5POLBKDM4E | |
| SCHEMBL6407663 | 0.81 | NPC1 (0.50) | KCNMA1HSPA5POLB | |
| SCHEMBL6408459 | 0.80 | ACLY (0.59) | KCNMA1ACLYKDM4E | |
| SCHEMBL6416161 | 0.80 | MEN1 (0.52) | KCNMA1ACLYHSPA5POLBTDP1 | |
| SCHEMBL6415355 | 0.80 | HSPA5 (0.44) | KCNMA1ACLYHSPA5POLBP2RX1 | |
| SCHEMBL6412941 | 0.80 | CA1 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124667-A1 | Oxamide inhibitors of plasminogen activator inhibitor-1 | CEREP SA (FR) | 2005-06-09 | — | — | US | claimed |
| US-20050124667-A1 | Oxamide inhibitors of plasminogen activator inhibitor-1 | CEREP SA (FR) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124667-A1 | Oxamide inhibitors of plasminogen activator inhibitor-1 | SERPINE1, SERPINC1, SERPINB1 | KCNMA1 2149/4885ACLY 2109/4885HSPA5 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.